Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

BACKGROUND: Among patients with glioblastoma (GBM) who progress on standard temozolomide, the optimal therapy is unknown. Resistance to temozolomide is partially mediated by O(6)-methylguanine-DNA methyltransferase (MGMT). Because MGMT may be depleted by prolonged temozolomide administration, dose-i...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Norden, Andrew D., Lesser, Glenn J., Drappatz, Jan, Ligon, Keith L., Hammond, Samantha N., Lee, Eudocia Q., Reardon, David R., Fadul, Camilo E., Plotkin, Scott R., Batchelor, Tracy T., Zhu, Jay-Jiguang, Beroukhim, Rameen, Muzikansky, Alona, Doherty, Lisa, Lafrankie, Debra, Smith, Katrina, Tafoya, Vida, Lis, Rosina, Stack, Edward C., Rosenfeld, Myrna R., Wen, Patrick Y.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Clinical Investigations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3688016/
https://ncbi.nlm.nih.gov/pubmed/23553268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/not040
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller